<DOC>
	<DOCNO>NCT01737866</DOCNO>
	<brief_summary>A phase 1 , open-label study subject normal renal function subject various degree renal insufficiency , include patient end-stage renal disease ( ESRD ) require hemodialysis . The primary objective evaluate single-dose PK AMG 423 subject various degree renal insufficiency , include patient end-stage renal disease require hemodialysis .</brief_summary>
	<brief_title>Pharmacokinetics Study AMG 423 Healthy Subjects Subjects With Various Degrees Renal Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Men woman â‰¥18 year age Laboratory test value ( clinical chemistry hematology ) within normal limit , ( test value normal range subject CKD [ group 1 3 5 ] ) , clinically acceptable investigator sponsor screen day 3 Free clinically significant disease condition ( ) ( consistent CKD subject group 1 3 5 ) require physician 's care and/or would interfere evaluation , procedure , participation study per investigator 's discretion ; Subjects whose second MDRD eGFR result screen period within 10 % first eGFR result Subjects receive function renal transplant within past year Subjects ESRD function hemodialysis access Subjects hemodynamic instability hemodialysis Subjects whose renal insufficiency due active autoimmune renal disease Subjects renal insufficiency ESRD require hemodialysis Troponin I &gt; upper limit normal ( ULN ) screen day 3 Subjects history heart disease unstable angina within last 3 month Subjects uncontrolled diabetes ( Hb1Ac &gt; 8 % ) and/or subject able unwilling adhere require fasting interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Heart , Failure , Renal , Insufficiency , Cardiac , Kidney , Hemodialysis , Impairment , omecamtiv mecarbil , cardiac myosin activator , CK-1827452</keyword>
</DOC>